A bipartisan coalition of over two-dozen federal lawmakers, including House Judiciary Chairman Bob Goodlatte (R-VA) and Matt Gaetz (R-FL), are backing newly introduced legislation — The Medical Cannabis Research Act of 2018 — to facilitate federally-approved clinical trials involving cannabis. Passage of this act would end the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes by requiring the licensing of additional manufacturers.
The director of the US National Institute on Drug Abuse (NIDA), Nora Volkow, believes that cannabidiol (CBD) – a nonpsychotropic cannabinoid – is “a safe drug with no addictive effects.”
Members of the US Senate at a hearing yesterday expressed skepticism in regard to federal policies limiting the ability of investigators to engage in clinical studies of marijuana’s health benefits. Senators heard from representatives from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), University of Mississippi Medical Center, Arrowhead Regional Medical Center and Project SAM on a variety of issues The hearing’s most noteworthy moment came when Nora Volkow, director of NIDA, acknowledged that the monopoly on marijuana cultivation for research purposes […]
It bears repeating that ample scientific research already exists to contradict cannabis’ federal, schedule I status as a substance without medical utility, lacking acceptable safety, and possessing a high potential of abuse. More clinical research is welcome, but unfortunately science has never driven marijuana policy. If it did, the United States would already have a very different policy in place.
Yavapai County Prosecutor Using Government Money To Oppose Marijuana Legalization
DEA Administrator Michele Leonhart filed paperwork today announcing that the agency is seeking to increase its marijuana production quota for the year 2015 by nearly three-fold.
The US Drug Enforcement Administration (DEA) has publicly announced in the Federal Register that it is increasing its marijuana production quota from 21 kilograms to 650 kilograms (about 1,443 pounds) in order to meet increasing demand for the plant from clinical investigators.
Adolescent consumption of alcohol and tobacco fell to historic lows while self-reported annual use of cannabis held steady, according to survey data released Wednesday by the University of Michigan at Ann Arbor — which has been sampling teens consumption of various licit and illicit substances since the mid-1970s. But you wouldn’t know these facts if you read today’s mainstream media headlines.
Washington, DC: I jumped into a cab Monday afternoon at the airport at the top of the hour, when the all-news radio station led with an almost hysterical-in-tone news flash of the Washington Post being sold to Amazon’s Jeff Bezos. While most of established Washington and media circles rightly buzz about this cataclysmic change in ownership…my mind has raced for nearly 48 hours thinking back to the PROFOUND influence the Washington Post has had in in maintaining cannabis prohibition—acting at times barely more than a government organ; a ‘rip-n-read’ anti-pot […]
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s news alerts and legislative advisories delivered straight to your in-box, sign up here.] The use of cannabis and cannabinoids appears to mitigate symptoms associated with post-traumatic stress disorder (PTSD), according to a new review of clinical and preclinical evidence published online in the scientific journal Drug Testing and Analysis. An international team of investigators from Germany, the United States, and the United Kingdom reported that the use of cannabis to “dramatically reduced” PTSD […]